------------------------------
OMB APPROVAL
------------------------------
OMB Number 3235-0362
Expires: January 31, 2005
Estimated average burden
hours per response ....... 1.0
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 5
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[_] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).
[_] Form 3 Holdings Reported
[_] Form 4 Transactions Reported
--------------------------------------------------------------------------------
1. Name and Address of Reporting Person*
Lai-Goldman, Myla P.
--------------------------------------------------------------------------------
(Last) (First) (Middle)
c/o Laboratory Corporation of America Holdings, 430 South Spring Street
--------------------------------------------------------------------------------
(Street)
Burlington, North Carolina 27215
--------------------------------------------------------------------------------
(City) (State) (Zip)
--------------------------------------------------------------------------------
2. Issuer Name and Ticker or Trading Symbol
Laboratory Corporation of America Holdings ("LH")
--------------------------------------------------------------------------------
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
--------------------------------------------------------------------------------
4. Statement for Month/Year
December 31, 2002
--------------------------------------------------------------------------------
5. If Amendment, Date of Original (Month/Year)
--------------------------------------------------------------------------------
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[_] Director [_] 10% Owner
[X] Officer (give title below) [_] Other (specify below)
Executive Vice President, Chief Scientific Officer and Medical Director
-----------------------------------------------------------------------
--------------------------------------------------------------------------------
7. Individual or Joint/Group Filing
(Check applicable line)
[X] Form Filed by One Reporting Person
[_] Form Filed by More than One Reporting Person
--------------------------------------------------------------------------------
================================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
================================================================================
5. 6.
4. Amount of Owner-
Securities Acquired (A) Securities ship
2A. or Disposed of (D) Beneficially Form: 7.
2. Deemed (Instr. 3, 4 and 5) Owned at End Direct Nature of
Transaction Execution 3. ------------------------- of Issuer's (D) or Indirect
1. Date Date, if Transaction (A) Fiscal Year Indirect Beneficial
Title of Security (Month/Day any (Month/ Code Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) Year) Day/Year) (Instr. 8) (D) and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 1/7/02 A 11,900 A D
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 2/14/02 A 17,600 A 106,867.2098 (1) D
------------------------------------------------------------------------------------------------------------------------------------
2,000 (2) I By children
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
(1) Amount shown reflects a 2-for-1 stock split effective on May 10, 2002.
Includes 442.2659 shares acquired on June 28, 2002 and 520.5865 shares
acquired on December 31, 2002 under the Laboratory Corporation of
America Holdings stock purchase plan.
(2) Dr. Lai-Goldman disclaims beneficial ownership of the 2,000 shares of
common stock held in her daughter's name.
(Over)
SEC 2270 (6-02)
FORM 5 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
================================================================================
5.
Number of 6.
3A. Derivative Date
2. 3. Deemed Securities Exercisable and
1. Conversion Trans- Execution Acquired (A) or Expiration Date
Title of or Exercise action Date, if 4. Disposed of (D) (Month/Day/Year)
Derivative Price of Date any Transaction (Instr. 3, 4 and 5) -----------------------
Security Derivative (Month/ (Month/ Code ------------------- Date Expiration
(Instr. 3) Security Day/Year) Day/Year) (Instr.8) (A) (D) Exercisable Date
------------------------------------------------------------------------------------------------------------------------------------
Non-Qualified
Stock Option (2) $78.68 1/7/02 A 17,700 (3) 1/7/12
------------------------------------------------------------------------------------------------------------------------------------
Non-Qualified
Stock Option (4) $87.06 2/14/02 A 25,200 (5) 2/14/12
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
7.
Title and Amount 9.
of Underlying Number of 10.
Securities Derivative Ownership 11.
(Instr. 3 and 4) 8. Securities of Derivative Nature of
---------------------------- Price of Beneficially Security: Indirect
Amount or Derivative Owned at End Direct (D) or Beneficial
Number of Security of Year Indirect (I) Ownership
Title Shares (Instr. 5) (Instr. 4) (Instr. 4) (Instr. 4)
----------------------------------------------------------------------------------------------------------------
Common
Stock 17,700 $78.68 35,400 (6) D
----------------------------------------------------------------------------------------------------------------
Common
Stock 25,200 $87.06 50,400 (6) D
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------
================================================================================================================
Explanation of Responses:
(2) Employee stock option (right to buy) granted pursuant to the Laboratory
Corporation of America Holdings 2000 Stock Incentive Plan.
(3) The option vests in three equal annual installments beginning on January
7, 2003.
(4) Employee stock option (right to buy) granted pursuant to the Laboratory
Corporation of America Holdings 2000 Stock Incentive Plan.
(5) The option vests in three equal annual installments beginning on February
14, 2003.
(6) Amount shown reflects a 2-for-1 stock split effective on May 10, 2002.
/s/ Bradford T. Smith February 14, 2003
--------------------------------------------- -----------------------
**Signature of Reporting Person Date
Bradford T. Smith, Attorney-in-Fact for
Myla P. Lai-Goldman
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one Reporting Person, see
Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB control number.
Page 2